Ovarian Cancer - Drug Pipeline Analysis and Market Forecasts to 2016

Jan. 18, 2010 - PRLog -- GlobalData forecasts the global ovarian cancer market to grow at 13.1% annually for the next seven years to reach $1,650 million by 2016. It was estimated to be at $697 million in 2009. This significant growth is primarily attributed to high prescription rates of multiple lines of chemotherapeutic drugs. In addition, successful launch of some of the molecular targeted therapies such as Avastin and abagovomab currently in Phase III may significantly stimulate market growth in near future. However, the low diagnosis rate and decreasing incidence rate will pose a barrier for market growth.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Ovarian-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

GlobalData found that there are more than 250 products in different stages of development. Avastin, currently in Phase III, is the most promising products in the pipeline. Avastin has shown encouraging response rates in pretreated patients and has a great potential in the ovarian cancer market. If approved, other pipeline candidates such as Opaxio, Yondelis, patupilone, Karenitecin, Telcyta and abagovomab currently in Phase III will provide alternative treatment options to current therapies,. These products are expected to meet certain extent of unmet needs and will give physicians more choice in treating ovarian cancer. It may also lead to an intensely competitive market landscape and the existing market leaders will have to be prepared to manage this dynamic. In summary, the global ovarian cancer market is heading towards a highly competitive landscape.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID...

Roche’s Avastin was the first anti-angiogenic drug to be approved in the cancer market. The drug is indicated for different type of cancers such as late stage colorectal, breast, lung, kidney, ovarian, pancreatic, renal and prostate cancers. Currently, the drug is being studied in Phase III clinical trial for treatment of recurrent ovarian cancer patients. In Phase II clinical trial, Avastin showed high response rates in heavily pretreated recurrent patients. The encouraging results from clinical trials and already proven efficacy in different cancer types make Avastin a most promising drug for treatment of recurrent ovarian cancer. Avastin will attract most investor’s attention in coming future. Apart from Roche (Genentech, Inc.); Cell Therapeutics, Inc., Novartis AG, PharmaMar and Menarini Group are holding promising molecules in their pipeline. The launch of these promising molecules may intensify competition in the near future.

GlobalData, the industry analysis specialist’s new report, “Ovarian Cancer – Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global ovarian cancer market. The report identifies the key trends shaping and driving the global ovarian cancer market. It also provides insights on the current competitive landscape and the emerging players expected to bring a significant shift in the market positioning of the existing market leaders. More importantly, the report gives valuable insights on the pipeline products within the global ovarian cancer sector.

For further details, please click or add the below link to your browser:
http://www.global-market-research-data.com/Report.aspx?ID=Ovarian-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016

Or visit our report store: http://www.globaldata.com/reportstore

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.